Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 5Completed 3Unknown 1Terminated 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 28Gynecologic 4Genitourinary 3Breast 2Thoracic 1Other solid neoplasm 1Head & Neck 1

Conditions

Solid Tumors 1

Interventions

Injections 9Interviews as Topic 4Cisplatin 4Carboplatin 4toripalimab 3fludarabine 3envafolimab 3Pemetrexed 3Iodine-125 3Immune Checkpoint Inhibitors 3Fluorodeoxyglucose F18 3tislelizumab 2pembrolizumab 2Paclitaxel 2Oxaliplatin 2Drug Therapy 2Cyclophosphamide 2Cryosurgery 2Capecitabine 2Blood Specimen Collection 2trastuzumab deruxtecan 1spartalizumab 1somatostatin receptor 2 1regorafenib 1olaparib 1nabiximols 1malic acid 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × lenvatinib × Other solid neoplasm × Clear all
NCT07417501 2026-02-18

Lenvatinib Plus PD-1 Inhibitor for Advanced Solid Tumors With 11q13 Amplification

Tongji Hospital

Phase 2 Not yet recruiting
60 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡